HomeCompareTBGNF vs JNJ

TBGNF vs JNJ: Dividend Comparison 2026

TBGNF yields 1176.47% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TBGNF wins by $78814195.17M in total portfolio value
10 years
TBGNF
TBGNF
● Live price
1176.47%
Share price
$0.17
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$78814195.20M
Annual income
$67,523,701,253,088.38
Full TBGNF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — TBGNF vs JNJ

📍 TBGNF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTBGNFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TBGNF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TBGNF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TBGNF
Annual income on $10K today (after 15% tax)
$100,000.00/yr
After 10yr DRIP, annual income (after tax)
$57,395,146,065,125.13/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, TBGNF beats the other by $57,395,146,061,139.13/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TBGNF + JNJ for your $10,000?

TBGNF: 50%JNJ: 50%
100% JNJ50/50100% TBGNF
Portfolio after 10yr
$39407097.62M
Annual income
$33,761,850,628,888.89/yr
Blended yield
85.67%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

TBGNF
No analyst data
Altman Z
-23.0
Piotroski
2/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TBGNF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTBGNFJNJ
Forward yield1176.47%2.13%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$78814195.20M$30.3K
Annual income after 10y$67,523,701,253,088.38$4,689.40
Total dividends collected$77969765.27M$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TBGNF vs JNJ ($10,000, DRIP)

YearTBGNF PortfolioTBGNF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$128,347$117,647.06$10,592$272.30+$117.8KTBGNF
2$1,548,514$1,411,182.61$11,289$357.73+$1.54MTBGNF
3$17,569,052$15,912,142.01$12,123$472.89+$17.56MTBGNF
4$187,523,354$168,724,468.35$13,141$629.86+$187.51MTBGNF
5$1,883,716,681$1,683,066,692.55$14,408$846.81+$1883.70MTBGNF
6$17,816,329,317$15,800,752,468.33$16,021$1,151.60+$17816.31MTBGNF
7$158,731,384,105$139,667,911,735.60$18,122$1,588.22+$158731.37MTBGNF
8$1,332,782,916,056$1,162,940,335,063.89$20,930$2,228.20+$1332782.90MTBGNF
9$10,551,863,503,163$9,125,785,782,982.70$24,792$3,191.91+$10551863.48MTBGNF
10$78,814,195,201,473$67,523,701,253,088.38$30,274$4,689.40+$78814195.17MTBGNF

TBGNF vs JNJ: Complete Analysis 2026

TBGNFStock

Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist which is in Phase II clinical trials for the treatment of DME. It has collaboration agreements with Bicycle Therapeutics, INC Research, and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.

Full TBGNF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this TBGNF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TBGNF vs SCHDTBGNF vs JEPITBGNF vs OTBGNF vs KOTBGNF vs MAINTBGNF vs ABBVTBGNF vs MRKTBGNF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.